Evidence map›Paper›PMID 32531665›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2020

Performance evaluation of the Aptima HIV-1 RNA Quant assay on the Panther system using the standard and dilution protocols.

Rebecca Rossetti, Tara Smith, Wei Luo, Jennifer Taussig, Mariah Valentine-Graves, Patrick Sullivan, Jessica M Ingersoll, Colleen S Kraft, Steve Ethridge, Laura Wesolowski and 4 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05690607 (Small Volume Blood Testing Validity and Acceptability for HIV-1 and Hepatitis B), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05690607 unknown statusnot on this mapstarted 2023, after this paper: background citation

Small Volume Blood Testing Validity and Acceptability for HIV-1 and Hepatitis B

TypeobservationalSponsorCentral and North West London NHS Foundation TrustRan2023 to 2024Enrolled300ConditionsHIV Infections, Hepatitis BArmsDoctors Laboratory TINIES small volume blood testing kit
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Rebecca RossettiDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, United States. Electronic address: nvp4@cdc.gov.
Tara SmithOak Ridge Institute for Science and Education Assigned to Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, United States.
Wei LuoDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, United States.
Jennifer TaussigDepartment of Epidemiology, Rollins School of Public Health, Emory University, United States.
Mariah Valentine-GravesDepartment of Epidemiology, Rollins School of Public Health, Emory University, United States.
Patrick SullivanDepartment of Epidemiology, Rollins School of Public Health, Emory University, United States.
Jessica M IngersollDepartment of Pathology and Laboratory Medicine, Emory University, United States.
Colleen S KraftDepartment of Pathology and Laboratory Medicine, Emory University, United States.
Steve EthridgeDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, United States.
Laura WesolowskiDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, United States.
Kevin P DelaneyDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, United States.
S Michele OwenDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, United States.
Jeffrey A JohnsonDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, United States.
Silvina MasciotraDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, United States.
Centers for Disease Control and Prevention · USEmory University · US

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Understanding disparities in effective HIV treatment and prevention: Involvement+R01AI112723 · NIAID · EMORY UNIVERSITY · PI SULLIVAN, PATRICK SEAN · 2015 to 2018
$3.1M
Intramural CDC HHS CC999999NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI112723
6 · The paper itself

Abstract

backgroundCurrently, FDA-approved HIV-1 viral load (VL) assays use venipuncture-derived plasma. The Hologic Panther system uses 0.7 mL total volume for the Aptima HIV-1 Quant Assay standard (APT-Quant-std) and dilution (APT-Quant-dil) protocols. However, smaller plasma volumes from fingerstick whole blood (FSB) collected in EDTA-microtainer tubes (MCT) could provide an easier sample collection method for HIV-1 VL testing.

objectivesTo evaluate the performance of the APT-Quant-std compared to the Roche CAP/CTM and Abbott m2000RT VL assays and an alternative APTQuant 1:7 dilution protocol, the latter using 100 μL of MCT-derived plasma from FSB. STUDY

designLinearity was determined using commercial HIV-1 RNA plasma controls. Dilutions ranging 1.56-2.95 log10 copies/mL were prepared to determine the APT-Quant-dil Limit of Quantitation (LOQ) using Probit analysis. Specificity of APT-Quant-std was calculated using 326 HIVnegative samples. To evaluate agreement, 329 plasma specimens were tested with APT-Quant-std, CAP/CTM, and m2000RT. Forty-seven matched venipuncture and MCT-derived plasma specimens were tested with APT-Quant-std and APT-Quant-dil.

resultsAmong the RNA controls, specificity was 99.69 % for APT-Quant-std. The R2 values were 0.988 (APT-Quant-std/CAP/CTM), 0.980 (APT-Quant-std/ m2000RT), and 0.997 (APT-Quant-std/APT-Quant-dil). The APT-Quant-dil LOQ was estimated at 2.7 log10 copies/mL (500 copies/mL) (95 %CI 2.62-2.87). At 2.3 log10 copies/mL (200 copies/mL), the overall agreement was 91.0 % for APT-Quant-std/CAP/CTM, 85.7 % for APT-Quant-std/m2000RT, and 82.9 % for APT-Quant-std/APT-Quant-dil. Quantified APT-Quant-std results were on average 0.2 log10 copies/mL higher than CAP/CTM and m2000RT and 0.14 log10 copies/mL higher than APT-Quant-dil.

conclusionAPT-Quant showed similar performance compared to the CAP/CTM and m2000RT assays and remains sensitive and accurate using the dilution protocol.

Indexed as

HIV-1HIV InfectionsHumansRNARNA, ViralSensitivity and SpecificityViral LoadRNARNA, ViralAptima HIV-1 quantHIV diagnosisMicrotainer preparation tubesSelf-collectionViral load

Identifiers

PMID32531665
PMCPMC7395893
OpenAlexW3030814139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.